Moderna, Inc. Contract Liability (Deferred Revenue)
Moderna, Inc. (MRNA) had Contract Liability (Deferred Revenue) of $295.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-07-31
- 2026-06-30: Contract with Customer, Liability, Current $295.00M.
- 2026-03-31: Contract with Customer, Liability, Current $102.00M.
- 2025-12-31: Contract with Customer, Liability, Current $99.00M.
- 2025-09-30: Contract with Customer, Liability, Current $163.00M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $295.00M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $102.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $99.00M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $163.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $218.00M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $125.00M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $153.00M 10-K · filed 2026-02-20 | |
| 2024-09-30 | $379.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $702.00M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $559.00M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $568.00M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $1.37B 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $1.04B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.22B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $2.04B 10-K · filed 2024-02-23 | |
| 2022-09-30 | $4.00B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $4.09B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $5.60B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $6.25B 10-K · filed 2023-02-24 | |
| 2021-09-30 | $7.98B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $7.30B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $7.53B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $3.87B 10-K · filed 2022-02-25 | $3.87B 10-K · filed 2021-02-26 |
| 2020-09-30 | $1.23B 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $45.24M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $58.84M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $63.31M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $70.19M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $83.40M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $73.96M 10-Q · filed 2019-05-09 | |
| 2019-01-01 | $81.78M 10-K · filed 2020-02-27 | |
| 2018-12-31 | $109.06M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |